These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. Eslam M; George J Aliment Pharmacol Ther; 2018 Apr; 47(7):1038-1039. PubMed ID: 29512910 [No Abstract] [Full Text] [Related]
43. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Rinella ME; Sanyal AJ Nat Rev Gastroenterol Hepatol; 2015 Feb; 12(2):65-6. PubMed ID: 25560844 [TBL] [Abstract][Full Text] [Related]
44. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407 [TBL] [Abstract][Full Text] [Related]
45. Obeticholic acid: towards first approval for NASH. Eslam M; Alvani R; Shiha G Lancet; 2019 Dec; 394(10215):2131-2133. PubMed ID: 31813639 [No Abstract] [Full Text] [Related]
46. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Guaraldi G; Maurice JB; Marzolini C; Monteith K; Milic J; Tsochatzis E; Bhagani S; Morse CG; Price JC; Ingiliz P; Lemoine M; Sebastiani G; Hepatology; 2020 May; 71(5):1831-1844. PubMed ID: 32052857 [TBL] [Abstract][Full Text] [Related]
47. Plecanatide, Nusinersen, and Obeticholic acid. Hussar DA; Douglas DK J Am Pharm Assoc (2003); 2017; 57(3):416-418. PubMed ID: 28506401 [No Abstract] [Full Text] [Related]
48. Trials and tribulations in drug development for nonalcoholic steatohepatitis. Sanyal AJ; Chalasani N Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2104-5. PubMed ID: 25117774 [No Abstract] [Full Text] [Related]
49. Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease. Lin CH; Kohli R Clin Transl Gastroenterol; 2018 Jun; 9(6):164. PubMed ID: 29955036 [No Abstract] [Full Text] [Related]
50. Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease. Mazzini GS; Khoraki J; Browning MG; Campos GM Cell Death Dis; 2018 Mar; 9(3):354. PubMed ID: 29500352 [No Abstract] [Full Text] [Related]
52. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Verbeke L; Farre R; Verbinnen B; Covens K; Vanuytsel T; Verhaegen J; Komuta M; Roskams T; Chatterjee S; Annaert P; Vander Elst I; Windmolders P; Trebicka J; Nevens F; Laleman W Am J Pathol; 2015 Feb; 185(2):409-19. PubMed ID: 25592258 [TBL] [Abstract][Full Text] [Related]
53. Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]. Rotman Y Dig Liver Dis; 2015 Dec; 47(12):1090. PubMed ID: 26382727 [No Abstract] [Full Text] [Related]
54. Authors' reply to the comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]. Zhu JD; Zhang QY; Mi MT Dig Liver Dis; 2015 Dec; 47(12):1090-1. PubMed ID: 26364558 [No Abstract] [Full Text] [Related]
55. Treatment of PBC-A step forward. Carbone M; Invernizzi P Liver Int; 2017 Apr; 37(4):503-505. PubMed ID: 28371102 [TBL] [Abstract][Full Text] [Related]
56. Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid. Eaton JE; Vuppalanchi R; Reddy R; Sathapathy S; Ali B; Kamath PS Hepatology; 2020 Apr; 71(4):1511-1514. PubMed ID: 31680292 [No Abstract] [Full Text] [Related]
57. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Andrade JM; Paraíso AF; de Oliveira MV; Martins AM; Neto JF; Guimarães AL; de Paula AM; Qureshi M; Santos SH Nutrition; 2014; 30(7-8):915-9. PubMed ID: 24985011 [TBL] [Abstract][Full Text] [Related]
58. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Liu J; Wang G; Jia Y; Xu Y Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109 [TBL] [Abstract][Full Text] [Related]
59. [Drugs clinical trials of nonalcoholic fatty liver disease: the present and future]. Mao YM Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):808-10. PubMed ID: 24516925 [No Abstract] [Full Text] [Related]
60. Resveratrol and liver disease: from bench to bedside and community. Bishayee A; Darvesh AS; Politis T; McGory R Liver Int; 2010 Sep; 30(8):1103-14. PubMed ID: 20557453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]